International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7899125
Original Article
Study of Clinical Spectrum of Abruptio Placentae and its Management at a Tertiary Care Hospital
 ,
 ,
 ,
 ,
Published
April 30, 2023
Abstract
Introduction: Placental abruption contributes almost 30% of all cases of antepartum haemorrhage. Both mother and foetus are at huge risk of maternal and perinatal morbidity and mortality. Aims And Objectives: To study the maternal and perinatal outcome incases of abruptio placentae at a tertiary care Hospital. Methods: This was a prospective observational study carried out in cases of abruptio placentae during a 2 year study period. Results: In present study, total 200 cases of abruption were observed. Most common age group in present study was 21-25 years. Abruptio placentae was common in gestational age above 37 weeks. In present study, 53% were vaginal deliveries, 45 % were delivered by LSCS, 2% by instrumental deliveries. Most common indication for LSCS was foetal distress(62.22%). In majority of (70%) of cases abruption was mixed type. (59.5%) cases had grade 2 abruption. Postpartum haemorrhage occurred in 30% cases and haemorrhagic shock was observed in 20% cases.89.5% cases required packed RBC transfusion. There were 4 cases of maternal mortality.65%babies required NICU admission, 30% were still births. 10% cases of perinatal mortality were there. Conclusion: Placental abruption is unpredictable and non-preventable, but maternal and perinatal morbidity and mortality can be reduced by adequate antenatal care, early detection and monitoring of risk factors, timely management at tertiary care level.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
2554 Views
500 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved